Notice NOT-CA-20-005 from the NIH Guide for Grants and Contracts

Notice NOT-OD-20-006 from the NIH Guide for Grants and Contracts

Notice NOT-OD-20-005 from the NIH Guide for Grants and Contracts

Notice NOT-HG-20-004 from the NIH Guide for Grants and Contracts

Notice NOT-OD-20-009 from the NIH Guide for Grants and Contracts

Notice NOT-MH-19-044 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-AI-19-059 from the NIH Guide for Grants and Contracts. The purpose of this initiative is to stimulate basic research, discovery, and early translational research to enable and accelerate the generation of highly efficacious pre-erythrocytic stage, sporozoite-based vaccines. Cross-fertilization and collaboration among investigators from malaria vaccine research and other basic research areas such as parasite biology, parasite genomics, pathogenesis, and host immunology are highly encouraged. The goal is to generate one or more promising vaccine candidates against human malaria that exhibit performance superior to currently available sporozoite-based vaccines and are suitable for further downstream process development and future clinical evaluation.

Notice NOT-HS-19-023 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-NR-20-001 from the NIH Guide for Grants and Contracts. This RFA encourages research to promote a greater understanding of the challenges faced by rural population groups, for the development (or adoption/adaptation) of evidence-based interventions that can reduce the health risks faced by rural Americans. Both prevention and treatment interventions are needed to address rural health issues. Prevention strategies should address and measure reductions in risk factors and enhancement of protective factors, while treatment approaches would seek to measure and address amelioration of health in individuals living with existing conditions. To accomplish these goals, the research community will be encouraged to use a wide range of culturally appropriate methodological approaches that can enhance access to and acceptability of interventions in rural settings, such as telehealth and community-based prevention research, where appropriate. It is our hope that research supported under this RFA will contribute to our knowledge of the sustainability of health promotion strategies in rural settings.

Funding Opportunity RFA-ES-20-005 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) supports Phase I (R43), Phase II (R44), Direct Phase II (R44) and Fast Track (R44) Small Business Innovative Research (SBIR) grant proposals from small businesses concerns (SBCs) to develop novel, physiologically-relevant in vitro screening systems (e.g., engineered 3-dimensional or organotypic models) using cells derived from animal species typically utilized for toxicological testing, which will replicate biological interactions and toxicological responses observed in animal tissues or organs, will produce assay data suitable for comparisons between in vitro and in vivo animal toxicology studies, and may ultimately provide alternative methods to reduce the use of animals in toxicity testing.

Notice NOT-MH-19-057 from the NIH Guide for Grants and Contracts

Notice NOT-GM-20-001 from the NIH Guide for Grants and Contracts

Notice NOT-HD-19-033 from the NIH Guide for Grants and Contracts

Notice NOT-AR-20-006 from the NIH Guide for Grants and Contracts

Notice NOT-HD-19-034 from the NIH Guide for Grants and Contracts

Notice NOT-NS-20-014 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-20-029 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to encourage grant applications that address the long term goal and objective of developing sustained release strategies for HIV treatment or prevention. Applications may propose treatment or prevention products delivered using sustained release platforms (oral, injection, implant or direct delivery to HIV target mucosa) that will provide a minimum of 1 week for oral (treatment) or a minimum of once a month for all other drug delivery systems for prevention and treatment.

Funding Opportunity RFA-AI-19-065 from the NIH Guide for Grants and Contracts. This initiative will support basic and translational research to address knowledge gaps that hinder the development and regulation of bacteriophage used to prevent and treat drug-resistant bacterial infections.

Notice NOT-HL-19-711 from the NIH Guide for Grants and Contracts

Notice NOT-HD-19-028 from the NIH Guide for Grants and Contracts